How do functional complement assays compare with protein quantification? Core Guide

Functional testing looks at the orchestra playing; quantitative tests count the musicians.
Functional complement screening assays like CH50 and AH50 measure the total lytic activity of the entire classical or alternative pathway—they tell you if the cascade can complete its job of lysing a target cell. Specific protein quantification methods (nephelometry, ELISA, radial immunodiffusion) measure the exact concentration of individual complement proteins, such as C3 or C4, irrespective of whether those molecules are biologically active. These two approaches are designed for fundamentally different questions: functional screening detects overall pathway integrity and hidden functional mutations, while quantitative assays track consumption, biosynthesis, or pinpoint a specific missing component. In modern diagnostic workflows they are not competitors—they are sequential partners.

The core insight: Functional assays (CH50/AH50) answer “Does the pathway work?” while quantitative immunoassays answer “How much of protein X is present?” A complete complement evaluation always starts with functional screening and then uses specific protein measurements to isolate the defect, following a simple algorithmic logic based on which pathway is affected.

The Two Diagnostic Windows into the Complement System

Functional Screening: Testing the Whole Orchestra

The CH50 assay evaluates the classical pathway by measuring the serum dilution required to lyse 50% of antibody-sensitized sheep erythrocytes. It requires every component from C1 through C9, plus C1 inhibitor, to be present and functional. If any one of these proteins is missing, inactive, or consumed, the CH50 value plummets.

The AH50 assay applies the same principle to the alternative pathway, using rabbit erythrocytes as the activator in a buffer containing EGTA and magnesium. EGTA chelates calcium, blocking classical pathway activation while leaving the magnesium-dependent alternative pathway intact. A normal AH50 requires functional C3, C5–C9, Factor B, Factor D, properdin, and regulatory proteins (Factors H and I).

The critical advantage: functional assays catch non-functional mutations. A patient can have a normal protein concentration by antigenic assay, but if a single amino acid substitution renders that protein biologically inactive, the CH50 or AH50 will be nearly absent. No quantification method can reveal this without functional testing.

Specific Protein Quantification: Counting Individual Instruments

Quantitative immunoassays—rate nephelometry, turbidimetry, ELISA, radial immunodiffusion—use polyclonal or monoclonal antibodies to measure the mass concentration of a specific protein. They detect the antigen whether the protein is fully active, partially degraded, or completely denatured.

These methods excel at:

• Tracking consumption: In autoimmune diseases like systemic lupus erythematosus, immune complexes activate complement, causing C3 and C4 levels to drop as they are consumed.
• Monitoring synthesis: Low C4 levels can indicate a genetic deficiency, while rising levels reflect increased hepatic production during an acute-phase response.
• Pinpointing a specific defect: Once functional screening localizes the problem to a particular pathway, quantitative assays identify exactly which protein is missing or reduced.

Because quantitative tests are fast, automatable, and have wide dynamic ranges, they serve as the high-throughput workhorses in clinical chemistry labs. However, they remain blind to functional competence.

How the Diagnostic Algorithm Works: Interpreting CH50, AH50, and Protein Levels

A sound diagnostic strategy pairs CH50/AH50 screening with targeted protein quantification using a simple decision tree.

Classical Pathway Defects (Low CH50, Normal AH50)

When CH50 is markedly reduced but AH50 is normal, the defect lies before the terminal pathway within the classical arm. This points to deficiencies in C1q, C1r, C1s, C4, or C2. Follow-up quantification of C4 and C2 typically reveals the culprit. In hereditary angioedema, C1 inhibitor functional defects show a similar pattern, though C4 antigenic levels are often low due to uncontrolled consumption.

Alternative Pathway Defects (Normal CH50, Low AH50)

A depressed AH50 with a normal CH50 indicates an alternative pathway–specific problem. The most common causes are Factor B, Factor D, or properdin deficiencies. Quantitative immunoassays for these factors confirm the precise missing component. This pattern can also appear when factor H is dysfunctional, leading to uncontrolled alternative pathway activation and secondary consumption.

Terminal Pathway or Severe Consumption (Both Low)

Low values in both CH50 and AH50 signal either a terminal pathway defect (C3, C5, C6, C7, C8, or C9 deficiency) or massive systemic complement consumption. Quantification of C3 and C4 is essential to distinguish between the two: very low C3 with low or normal C4 suggests a terminal component deficiency or alternative pathway overactivation; simultaneous depression of both C3 and C4 usually reflects classical pathway–mediated consumption, as seen in active lupus nephritis. Targeted measurement of C5–C9 proteins finalizes the diagnosis.

Understanding the Trade-offs

No single test covers all bases. Choosing wrong leads to misinterpretation.

Sensitivity for Functional Mutations

The unarguable strength of functional assays—detecting inactive proteins with normal antigenic levels—becomes a blind spot for quantitative tests. A patient with a normal C3 level by nephelometry can still have a non-functional C3 molecule and suffer from recurrent infections as if they were C3-deficient. Only the CH50 and AH50 will reveal this.

Preanalytical Sensitivity and Sample Requirements

Functional assays are exquisitely sensitive to preanalytical handling. Delayed serum separation, improper storage temperature, or repeated freeze–thaw cycles degrade complement activity, leading to falsely low CH50/AH50 values. Quantitative immunoassays are far more robust because they measure stable antigenic epitopes. For reliable functional testing, specimens must be processed quickly and kept at −70°C if not assayed immediately.

Interpretation Pitfalls in Inflammatory States

Complement proteins are acute-phase reactants. A normal or even elevated C3 or C4 level does not rule out consumption if the baseline was high due to inflammation. A patient might have active immune complex disease, consuming complement, yet still show a C4 level within the “normal” range. Here, a low CH50 provides the true picture of ongoing consumption that a single quantitative value might disguise. Serial measurements and paired functional-quantitative data are far more informative than single-point antigenic levels.

Making the Right Choice for Your Clinical Question

The most effective diagnostic approach aligns the test choice with the clinical scenario. Tailor your panel accordingly.

• If your primary focus is initial screening for a suspected complement deficiency: Start with CH50 and AH50. Zero activity in one or both pathways guides you directly to the underlying defect, and only then order specific protein quantification for the suspect components.
• If your primary focus is monitoring disease activity in lupus or other immune complex diseases: Use serial quantitative C3 and C4 measurements for their speed and reproducibility, but perform a baseline CH50 to establish the functional correlate. A falling CH50 adds confidence that low C3/C4 truly reflects consumption.
• If your primary focus is detecting a hidden functional mutation despite normal antigenic levels: Functional assays are non-negotiable. No concentration-based test will find the defect; CH50 and AH50 are the only tools that can expose it.
• If your primary focus is high-throughput laboratory workflow: Automate quantitative nephelometry for routine monitoring, but maintain a reflex pathway to functional testing whenever results are discordant or clinical suspicion remains high.

A thoughtful combination of functional screening and targeted protein quantification transforms a static lab value into a dynamic map of complement health—ensuring no silent functional defect goes undetected and no disease activity is over- or underestimated.

Summary Table:

Developing or optimizing your complement assay kits? CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic.

Contact CamelBio today to discuss your IVD raw material requirements and functional assay development needs!